Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01873495 · ClinicalTrials.gov registry record · Phase 2
Omacetaxine for Consolidation and Maintenance
A Phase 2 study, sponsored by Emory University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT01873495 is a Phase 2 study that was terminated before completion, run by Emory University. The registered enrollment target is 7 participants.
The verdict
NCT01873495, a Phase 2 study, was terminated before completion, sponsored by Emory University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
The purpose of this pilot study is to assess the safety and tolerability of omacetaxine for consolidation in patients age 55 and older with acute myelogenous leukemia (AML) in first complete remission following induction with cytarabine and an anthracycline, and also to assess the safety and tolerability of omacetaxine for maintenance in patients age 55 and older with acute AML in first complete remission following 3 consolidation courses with omacetaxine.
Interventions
- DRUG Omacetaxine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2013-05 |
| Est. Completion | 2018-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01873495
The ClinicalTrials.gov registry entry for NCT01873495 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Omacetaxine is the first listed.
NCT01873495 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01873495 about?
NCT01873495 is a clinical study titled "Omacetaxine for Consolidation and Maintenance". The purpose of this pilot study is to assess the safety and tolerability of omacetaxine for consolidation in patients age 55 and older with acute myelogenous leukemia (AML) in first complete remission following induction with cytarabine and an anthracycline, and also to assess the safety and tolerab...
What is the current status of trial NCT01873495?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2013-05. Estimated completion is 2018-07.
What interventions are being tested in trial NCT01873495?
The interventions under investigation include: Omacetaxine (DRUG).
Who is sponsoring clinical trial NCT01873495?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.